You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

GSL synthetase inhibitor

Showing 1 - 25 of 7,417
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Solid Tumor, Hematologic Malignancy Trial in Beijing (Eliglustat, Immune checkpoint inhibitor)

Recruiting
  • Solid Tumor
  • Hematologic Malignancy
  • Beijing, China
    Department of Biotherapeutic, Chinese PLA General Hospital
Apr 28, 2022

Hereditary Spastic Paraparesis Trial in Pisa (Miglustat 100 MG)

Completed
  • Hereditary Spastic Paraparesis
  • Miglustat 100 MG
  • Pisa, PI, Italy
    IRCCS Fondazione Stella Maris
Apr 1, 2022

Environmental Risk Factors for the Anti-synthetase Syndrome

Recruiting
  • Myositis
  • +4 more
    • Bethesda, Maryland
    • +1 more
    Jan 7, 2023

    Glycosphingolipid and Glycoprotein Lysosomal Storage Disorders

    Recruiting
    • Neurological Regression
    • +3 more
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      Jan 14, 2023

      Advanced Solid Tumor Trial in Nashville, Haifa, Tel Aviv (MTB-9655)

      Recruiting
      • Advanced Solid Tumor
      • Nashville, Tennessee
      • +2 more
      Dec 15, 2021

      Standardization of Quantitative Muscle Ultrasonographic

      Not yet recruiting
      • Muscle Disease
      • ultrasound
      • (no location specified)
      Jan 14, 2022

      Metastatic Melanoma, Skin Cancer, Tumor Trial in New York (ADI PEG 20)

      Completed
      Has Results
      • Metastatic Melanoma
      • +2 more
      • ADI PEG 20
      • New York, New York
      • +1 more
      Oct 3, 2022

      Peripheral T Cell Lymphoma Trial in Beijing (Linperlisib in combined with Chidamide)

      Recruiting
      • Peripheral T Cell Lymphoma
      • Linperlisib in combined with Chidamide
      • Beijing, Beijing/China, China
      • +1 more
      Oct 9, 2023

      Cutaneous T-cell Lymphoma Trial in Beijing (Linperlisib in combined with Chidamide)

      Recruiting
      • Cutaneous T-cell Lymphoma
      • Linperlisib in combined with Chidamide
      • Beijing, Beijing, China
        Peking Union Medical College Hospital
      Sep 8, 2023

      Cervical Cancer Trial in Amsterdam (Anti-PD-1 antibody balstilimab)

      Not yet recruiting
      • Cervical Cancer
      • Anti-PD-1 antibody balstilimab
      • Amsterdam, Netherlands
        Amsterdam UMC
      Oct 17, 2023

      Interstitial Lung and Liver Disease, Infantile Liver Failure Syndrome 1, Neurologic, Endocrine and Pancreatic Disease,

      Not yet recruiting
      • Interstitial Lung and Liver Disease
      • +3 more
      • Procedure/Surgery
      • Paris, France
        Hôpital Necker-Enfants Malades
      Aug 22, 2022

      Hepatocellular Carcinoma (HCC) Trial in Taiwan (Chidamide, Regorafenib)

      Recruiting
      • Hepatocellular Carcinoma (HCC)
      • Kaohsiung, Taiwan
      • +4 more
      Mar 14, 2023

      HIV Trial in Las Vegas, Austin (VH4004280, Placebo)

      Not yet recruiting
      • HIV Infections
      • Las Vegas, Nevada
      • +1 more
      Aug 21, 2023

      Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer Trial (OP-1250, Fulvestrant, Anastrozole)

      Not yet recruiting
      • Breast Cancer
      • +4 more
      • (no location specified)
      Aug 31, 2023

      Chronic Kidney Disease Trial (Part A - Lorundrostat QD + Dapaglifozin QD, Part A - Lorundrostat QD, Part B - Lorundrostat QD

      Not yet recruiting
      • Chronic Kidney Disease
      • Part A - Lorundrostat QD + Dapaglifozin QD
      • +2 more
      • (no location specified)
      Nov 27, 2023

      Differentiated Thyroid Cancer Trial in Pavia (Pembrolizumab)

      Not yet recruiting
      • Differentiated Thyroid Cancer
      • Pavia, Lombardia, Italy
        Istituti Clinici Scientifici Maugeri
      May 5, 2023

      Advanced Pancreatic Adenocarcinoma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma Trial in Boston (Zentalis, Gemzar)

      Not yet recruiting
      • Advanced Pancreatic Adenocarcinoma
      • +2 more
      • Boston, Massachusetts
      • +1 more
      Aug 23, 2023

      Blood Vessel Function in Postmenopausal Women With Breast Cancer

      Active, not recruiting
      • Breast Cancer
      • Rochester, Minnesota
        Mayo Clinic
      Jan 17, 2023

      Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma, Recurrent Adenoid Cystic Carcinoma Trial in Boston (CB-103,

      Not yet recruiting
      • Adenoid Cystic Carcinoma
      • +2 more
      • Boston, Massachusetts
        Dana Farber Cancer Institute
      Mar 14, 2023

      Healthy Trial in Biberach (BI 1810631, Itraconazole)

      Recruiting
      • Healthy
      • Biberach, Germany
        Humanpharmakologisches Zentrum Biberach
      Apr 27, 2023

      Acute Myeloid Leukemia (AML) Trial in Birmingham, San Francisco, New York (ZN-d5 ZN-c3, ZN-c3)

      Recruiting
      • Acute Myeloid Leukemia (AML)
      • Birmingham, Alabama
      • +2 more
      Jan 3, 2023

      Vonoprazan, Helicobacter Pylori Infection, Proton Pump Inhibitor Trial in Hangzhou (Tegoprazan, Esomeprazole)

      Active, not recruiting
      • Vonoprazan
      • +2 more
      • Hangzhou, Zhejiang, China
        Hangzhou first people's Hospital
      Dec 2, 2022

      Atypical Hemolytic Uremic Syndrome (aHUS) Trial in Worldwide (Ravulizumab)

      Active, not recruiting
      Has Results
      • Atypical Hemolytic Uremic Syndrome (aHUS)
      • Ravulizumab
      • Aurora, Colorado
      • +19 more
      Nov 16, 2022

      Perioperative Fluid Management Trial in Istanbul (isotonic solution, Noradrenaline)

      Recruiting
      • Perioperative Fluid Management
      • Istanbul, Fatih, Turkey
        Istanbul University, Department of Anesthesiology
      Feb 16, 2023

      Vonoprazan, Helicobacter Pylori Infection, Proton Pump Inhibitor Trial in Hangzhou (Vonoprazan Tablets, Amoxicillin Capsules,

      Recruiting
      • Vonoprazan
      • +2 more
      • Vonoprazan Tablets
      • +2 more
      • Hangzhou, Zhejiang, China
        Hangzhou first people's Hospital
      Nov 23, 2022